{"id":"https://openalex.org/W2013243363","doi":"https://doi.org/10.1136/bmj.f740","title":"Drug companies lobby against generic versions of biologics","display_name":"Drug companies lobby against generic versions of biologics","publication_year":2013,"publication_date":"2013-02-04","ids":{"openalex":"https://openalex.org/W2013243363","doi":"https://doi.org/10.1136/bmj.f740","mag":"2013243363","pmid":"https://pubmed.ncbi.nlm.nih.gov/23381589"},"language":"en","primary_location":{"id":"doi:10.1136/bmj.f740","doi":"https://doi.org/10.1136/bmj.f740","is_oa":false,"landing_page_url":"https://doi.org/10.1136/bmj.f740","pdf_url":null,"source":{"id":"https://openalex.org/S4393917726","display_name":"BMJ","issn_l":"1756-1833","issn":["1756-1833"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ","raw_type":"journal-article"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113613383","display_name":"MIRIAM E. TUCKER","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"M. E. Tucker","raw_affiliation_strings":["Washington, DC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington, DC","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5113613383"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"346","issue":"feb04 2","first_page":"f740","last_page":"f740"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8788999915122986,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8788999915122986,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.1200999990105629,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9959999918937683},{"id":"https://openalex.org/keywords/generic-drugs","display_name":"generic drugs","score":0.7900000214576721},{"id":"https://openalex.org/keywords/biologic-drugs","display_name":"biologic drugs","score":0.699999988079071},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.7089999914169312},{"id":"https://openalex.org/keywords/state-legislation","display_name":"state legislation","score":0.7649999856948853},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.7229999899864197},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.8199999928474426},{"id":"https://openalex.org/keywords/prescription-access","display_name":"prescription access","score":0.3619999885559082}],"concepts":[{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5946590900421143},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.5107810497283936},{"id":"https://openalex.org/C2522767166","wikidata":"https://www.wikidata.org/wiki/Q2374463","display_name":"Data science","level":1,"score":0.45204877853393555},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.4184539318084717},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35227710008621216},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.21239694952964783}],"mesh":[{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008119","descriptor_name":"Lobbying","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016568","descriptor_name":"Drugs, Generic","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1136/bmj.f740","doi":"https://doi.org/10.1136/bmj.f740","is_oa":false,"landing_page_url":"https://doi.org/10.1136/bmj.f740","pdf_url":null,"source":{"id":"https://openalex.org/S4393917726","display_name":"BMJ","issn_l":"1756-1833","issn":["1756-1833"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ","raw_type":"journal-article"},{"id":"pmid:23381589","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23381589","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ (Clinical research ed.)","raw_type":"News"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1987296090","https://openalex.org/W7100907943","https://openalex.org/W2010239837","https://openalex.org/W3006379403","https://openalex.org/W2965938015","https://openalex.org/W4252644969","https://openalex.org/W2322267609","https://openalex.org/W2170271088","https://openalex.org/W2803641020","https://openalex.org/W1965081089"],"abstract_inverted_index":{"Biotechnology":[0],"companies":[1],"have":[2],"launched":[3],"a":[4],"lobbying":[5],"initiative":[6],"to":[7,9,40,44,100,121],"try":[8],"stop":[10],"or":[11,72],"slow":[12],"down":[13],"the":[14,26,48,62,82,88,106],"introduction":[15],"of":[16,19,47,51,61,105,111,125],"generic":[17,116],"versions":[18,46,50,60,124],"expensive":[20],"biological":[21,52],"drugs.":[22,128],"State":[23],"legislatures":[24],"across":[25],"United":[27],"States":[28],"are":[29,54,80,93,98,119,131],"introducing":[30],"bills":[31],"that":[32],"could":[33],"make":[34],"it":[35],"more":[36],"difficult":[37],"for":[38,42,102],"doctors":[39],"prescribe\u2014and":[41],"patients":[43],"obtain\u2014cheaper":[45],"drugs.\n\nGeneric":[49],"drugs":[53,65,86],"known":[55],"as":[56,67,70],"biosimilars.":[57],"The":[58,90],"original":[59],"biologics":[63],"include":[64],"such":[66],"rituximab":[68],"(marketed":[69],"Rituxan":[71],"MabThera),":[73],"trastuzumab":[74],"(Herceptin),":[75],"and":[76],"bevacizumab":[77],"(Avastin).":[78],"These":[79],"among":[81],"best":[83],"selling":[84],"anticancer":[85],"in":[87,95],"world.":[89],"drugs,":[91,117],"which":[92],"produced":[94],"cell":[96],"systems,":[97],"said":[99],"account":[101],"about":[103],"25%":[104],"US":[107],"annual":[108],"drug":[109],"bill":[110],"$320bn":[112],"(\u00a3205bn;":[113],"\u20ac235bn).\n\nLike":[114],"other":[115],"biosimilars":[118],"designed":[120],"be":[122],"cheaper":[123],"brand":[126],"name":[127],"But":[129],"they":[130],"created":[132],"by":[133],"\u2026":[134]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}